|
||
 |
||
|
Zyban tablets contain the active ingredient bupropion hydrochloride, which is a medicine used to help people who are dependent on nicotine to give up smoking. It acts in the brain but is not the same as nicotine replacement therapy. The effectiveness of Zyban as an aid to smoking cessation was demonstrated in two studies. Over 1,500 chronic smokers who smoked at least 15 cigarettes a day participated in these studies. In one study, Zyban was compared to placebo; in the other study, Zyban was evaluated versus placebo, a nicotine patch, and in combination with the patch. In both studies, all patients received brief individual smoking cessation counseling. In the study involving the patch, patients treated with Zyban had significantly higher 4-week quit rates than those treated with the patch. Patients treated with the combination of Zyban and the patch had significantly higher quit rates than those treated with the patch alone. Quit rates with combination therapy, while higher, were not statistically higher than quit rates with Zyban alone. The 4-week quit rates from this study were 23% for placebo; 36% for the patch; 49% for Zyban; and 58% for the combination of Zyban and the patch. For many patients, treatment with Zyban reduced withdrawal symptoms. Withdrawal symptoms showing the most pronounced reductions were: irritability, frustration or anger, anxiety, difficulty concentrating, restlessness, and depressed mood or negative affect. In patients treated with Zyban there was also evidence of a reduction in craving for cigarettes or urge to smoke. |
||
|
||
|
||
|
||
|
- CHECKOUT
- English
- German
- US Dollar
- Euro
- UK Pound
- Canadian Dollar
- Swiss Frank
- Australian Dollar
